[go: up one dir, main page]

MX2019011040A - Composiciones y metodos para potenciar la expresion genica. - Google Patents

Composiciones y metodos para potenciar la expresion genica.

Info

Publication number
MX2019011040A
MX2019011040A MX2019011040A MX2019011040A MX2019011040A MX 2019011040 A MX2019011040 A MX 2019011040A MX 2019011040 A MX2019011040 A MX 2019011040A MX 2019011040 A MX2019011040 A MX 2019011040A MX 2019011040 A MX2019011040 A MX 2019011040A
Authority
MX
Mexico
Prior art keywords
methods
compositions
gene expression
enhance gene
expression
Prior art date
Application number
MX2019011040A
Other languages
English (en)
Inventor
Keravala Annahita
Original Assignee
Adverum Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adverum Biotechnologies Inc filed Critical Adverum Biotechnologies Inc
Publication of MX2019011040A publication Critical patent/MX2019011040A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente descripcion proporciona casetes de polinucleotidos, vectores de expresion y metodos para la expresion de un gen en celulas de mamifero.
MX2019011040A 2017-03-17 2018-03-16 Composiciones y metodos para potenciar la expresion genica. MX2019011040A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762472892P 2017-03-17 2017-03-17
PCT/US2018/022996 WO2018170473A1 (en) 2017-03-17 2018-03-16 Compositions and methods for enhanced gene expression

Publications (1)

Publication Number Publication Date
MX2019011040A true MX2019011040A (es) 2020-01-20

Family

ID=63523675

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019011040A MX2019011040A (es) 2017-03-17 2018-03-16 Composiciones y metodos para potenciar la expresion genica.

Country Status (14)

Country Link
US (3) US11773406B2 (es)
EP (2) EP3596213A4 (es)
JP (2) JP7343903B2 (es)
KR (1) KR102616820B1 (es)
CN (1) CN110546257B (es)
AU (1) AU2018234918B2 (es)
BR (1) BR112019019158A2 (es)
CA (1) CA3054942A1 (es)
EA (1) EA201992001A1 (es)
IL (1) IL268788B2 (es)
MX (1) MX2019011040A (es)
SG (1) SG11201907653QA (es)
WO (1) WO2018170473A1 (es)
ZA (1) ZA202310779B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102288849B1 (ko) 2014-03-17 2021-08-12 애드베룸 바이오테크놀로지스, 인코포레이티드 원추세포에서 증강된 유전자 발현을 위한 조성물 및 방법
AU2016226289B2 (en) 2015-03-02 2021-04-29 Adverum Biotechnologies, Inc. Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
GB2545763A (en) 2015-12-23 2017-06-28 Adverum Biotechnologies Inc Mutant viral capsid libraries and related systems and methods
US11192925B2 (en) 2016-10-19 2021-12-07 Adverum Biotechnologies, Inc. Modified AAV capsids and uses thereof
BR112019019158A2 (pt) 2017-03-17 2020-05-05 Adverum Biotechnologies, Inc. composições e métodos para expressão genética melhorada
CA3083472A1 (en) * 2017-11-27 2019-05-31 4D Molecular Therapeutics Inc. Adeno-associated virus variant capsids and use for inhibiting angiogenesis
US20210301285A1 (en) * 2018-08-02 2021-09-30 Novozymes A/S Preparation of Combinatorial Libraries of DNA Constructs
KR20210135267A (ko) 2019-03-04 2021-11-12 애드베룸 바이오테크놀로지스, 인코포레이티드 반대측 눈에 대한 aav 유전자 요법의 순차적 유리체내 투여
SG11202109426YA (en) * 2019-03-06 2021-09-29 Generation Bio Co Non-active lipid nanoparticles with non-viral, capsid free dna
CA3148376A1 (en) 2019-09-11 2021-03-18 Mehdi Gasmi Methods of treating retinal neovascular diseases using aav2 variants encoding aflibercept________________________________
KR20220062352A (ko) * 2019-09-11 2022-05-16 애드베룸 바이오테크놀로지스, 인코포레이티드 아플리베르셉트를 코딩하는 aav2 변이체를 사용하여 안구 신생혈관 질환을 치료하는 방법
US20210100856A1 (en) * 2019-09-11 2021-04-08 Adverum Biotechnologies, Inc. Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept
KR102798616B1 (ko) * 2019-12-20 2025-04-22 (주)셀트리온 목적 단백질의 고발현을 위한 인트론을 포함하는 발현 카세트 및 이의 이용
KR102346159B1 (ko) * 2020-02-20 2022-01-03 국립암센터 고효율 발현 벡터 및 이의 용도
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
US20230117172A1 (en) * 2020-03-27 2023-04-20 Allen Institute Artificial expression constructs for selectively modulating gene expression in non-neuronal brain cells
US12173304B2 (en) * 2020-07-08 2024-12-24 Neuracle Genetics Inc. Intron fragments
CN113817775B (zh) * 2020-08-25 2023-02-17 南京吉迈生物技术有限公司 修饰的阿柏西普、组合物、方法及其在基因治疗中的应用
CN114250227A (zh) * 2020-09-25 2022-03-29 北京安龙基因医药技术有限公司 用于高水平表达外源基因的表达载体
CN114250226A (zh) * 2020-09-25 2022-03-29 北京安龙基因医药技术有限公司 用于高水平表达外源基因的表达载体
US20240117377A1 (en) * 2021-02-02 2024-04-11 Allen Institute Artificial expression constructs for modulating gene expression in gabaergic neurons and astrocytes
KR20240005764A (ko) 2021-04-27 2024-01-12 애드베룸 바이오테크놀로지스, 인코포레이티드 아플리베르셉트를 코딩하는 aav2 변이체를 사용하여 안구 질환을 치료하는 방법
CA3224488A1 (en) * 2021-07-08 2023-01-12 Tenaya Therapeutics, Inc. Optimized expression cassettes for gene therapy
EP4473120A2 (en) * 2022-01-31 2024-12-11 Trames Bio, Inc. Expression cassettes for treating epilepsy and neuropathic pain
JP2025506383A (ja) 2022-02-02 2025-03-11 アドヴェラム バイオテクノロジーズ， インコーポレイテッド アフリベルセプトをコードするａａｖ２バリアントを使用して眼内血管新生疾患を処置する方法
WO2023158990A1 (en) 2022-02-16 2023-08-24 Adverum Biotechnologies, Inc. Method of reducing cst fluctuation in neovascular amd by a recombinant adeno-associated virus
WO2023225455A2 (en) * 2022-05-18 2023-11-23 Visgenx, Inc. Synthetic aav genomes for improved gene delivery
EP4421176A4 (en) * 2022-12-29 2025-01-01 Themedium Therapeutics Co., Ltd NON-ENVELOPED 5'-UNTRANSLATED REGIONAL ELEMENT AND USE THEREOF
WO2024211831A1 (en) 2023-04-05 2024-10-10 Adverum Biotechnologies, Inc. Immune landscape signatures for ocular inflammation
WO2025073297A1 (zh) * 2023-10-06 2025-04-10 甘李药业股份有限公司 表达抗vegf融合蛋白的aav病毒载体及其用途
CN120230798A (zh) * 2023-12-29 2025-07-01 上海朗昇生物科技有限公司 用于视网膜基因递送的重组腺相关病毒载体及其应用
WO2026006785A2 (en) 2024-06-28 2026-01-02 Adverum Biotechnologies, Inc. Melanopsin variants for vision restoration

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
ES2230542T3 (es) 1993-03-25 2005-05-01 MERCK & CO., INC. Inhibidor del factor de crecimiento celular endotelial vascular.
US20020168342A1 (en) 1994-11-03 2002-11-14 Cell Genesys, Inc. Novel adenoviral vectors, packaging cell lines, recombinant adenoviruses and methods
US6040183A (en) 1995-06-07 2000-03-21 University Of North Carloina At Chapel Hill Helper virus-free AAV production
US6093570A (en) 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
US6087129A (en) 1996-01-19 2000-07-11 Betagene, Inc. Recombinant expression of proteins from secretory cell lines
DE69824859T2 (de) 1997-04-14 2005-08-04 Cell Genesys, Inc., Foster City Methoden zur erhöhung der effizienz rekombinanter aav produkte
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7629153B2 (en) 2001-08-02 2009-12-08 Research Development Foundation Methods and compositions relating to improved lentiviral vector production systems
US8021875B2 (en) 2001-08-27 2011-09-20 Roche Madison Inc. Methods for expression of transgenes
US7858367B2 (en) 2002-04-30 2010-12-28 Duke University Viral vectors and methods for producing and using the same
AU2003278695A1 (en) * 2002-05-28 2004-02-02 Maxygen, Inc. Nucleic acid vectors
GB0220467D0 (en) 2002-09-03 2002-10-09 Oxford Biomedica Ltd Composition
AR043017A1 (es) 2003-02-03 2005-07-13 Japan Immuno Inc Vector de alta expresion para celulas animales
US7186699B2 (en) 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
US9233131B2 (en) 2003-06-30 2016-01-12 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
US9441244B2 (en) 2003-06-30 2016-09-13 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
WO2005005644A1 (en) 2003-07-11 2005-01-20 Cytos Biotechnology Ag Gene expression system
US20070196389A1 (en) 2005-11-18 2007-08-23 The Ohio State University Research Foundation Viral gene products and methods for vaccination to prevent viral associated diseases
RU2524431C2 (ru) * 2007-09-26 2014-07-27 Интрексон Корпорейшн Синтетические 5 utr (нетранслируемые области), экспрессионные векторы и способ повышения трансгенной экспрессии
CN101970655B (zh) 2008-01-15 2014-03-05 Abbvie公司 改良哺乳动物表达载体及其用途
US8663624B2 (en) 2010-10-06 2014-03-04 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
SMT202000386T1 (it) 2011-04-22 2020-09-10 Univ California Virioni di virus adeno-associato con capside variante e relativi metodi di utilizzo
TWI698240B (zh) 2012-05-15 2020-07-11 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
US8975042B2 (en) * 2012-12-21 2015-03-10 Dna Twopointo, Inc. Fluorescent and colored proteins and methods for using them
ES2897508T3 (es) 2013-05-31 2022-03-01 Univ California Variantes de virus adenoasociados y métodos de uso de las mismas
KR102234695B1 (ko) 2014-02-06 2021-04-02 젠자임 코포레이션 황반 변성을 치료하고 예방하기 위한 조성물 및 방법
KR102288849B1 (ko) 2014-03-17 2021-08-12 애드베룸 바이오테크놀로지스, 인코포레이티드 원추세포에서 증강된 유전자 발현을 위한 조성물 및 방법
LT3129487T (lt) * 2014-04-09 2020-12-28 Dna Twopointo Inc. Patobulinti nukleorūgščių konstruktai, skirti eukariotinio geno raiškai
US10041077B2 (en) 2014-04-09 2018-08-07 Dna2.0, Inc. DNA vectors, transposons and transposases for eukaryotic genome modification
MX2017005834A (es) 2014-11-05 2017-11-17 Voyager Therapeutics Inc Polinucleotidos aad para el tratamiento de la enfermedad de parkinson.
AU2016226289B2 (en) 2015-03-02 2021-04-29 Adverum Biotechnologies, Inc. Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
JP6544565B2 (ja) * 2015-04-28 2019-07-17 国立大学法人広島大学 哺乳動物細胞内で目的遺伝子の発現を高める方法およびキット、並びに、その利用
GB2545763A (en) 2015-12-23 2017-06-28 Adverum Biotechnologies Inc Mutant viral capsid libraries and related systems and methods
AU2017257169B2 (en) 2016-04-29 2021-07-08 Adverum Biotechnologies, Inc. Evasion of neutralizing antibodies by a recombinant adeno-associated virus
MX2018014256A (es) * 2016-05-20 2019-08-16 Harvard College Metodos de terapia genica para enfermedades y condiciones relacionadas con la edad.
RS63282B1 (sr) 2016-06-16 2022-06-30 Adverum Biotechnologies Inc Kompozicije i postupci za smanjenje očne neovaskularizacije
AU2017286673B2 (en) 2016-06-16 2021-06-24 Adverum Biotechnologies, Inc. Treatment of AMD using AAV2 variant with aflibercept
US11192925B2 (en) 2016-10-19 2021-12-07 Adverum Biotechnologies, Inc. Modified AAV capsids and uses thereof
WO2018160686A1 (en) 2017-02-28 2018-09-07 Adverum Biotechnologies, Inc. Modified aav capsids and uses thereof
BR112019019158A2 (pt) 2017-03-17 2020-05-05 Adverum Biotechnologies, Inc. composições e métodos para expressão genética melhorada

Also Published As

Publication number Publication date
IL268788A (en) 2019-10-31
US20200010851A1 (en) 2020-01-09
IL268788B1 (en) 2025-01-01
CN110546257B (zh) 2024-03-01
EA201992001A1 (ru) 2020-01-24
AU2018234918A1 (en) 2019-09-12
WO2018170473A1 (en) 2018-09-20
CN110546257A (zh) 2019-12-06
US11352644B2 (en) 2022-06-07
JP7360208B2 (ja) 2023-10-12
KR102616820B1 (ko) 2023-12-21
US11773406B2 (en) 2023-10-03
US20210040501A1 (en) 2021-02-11
US20230257777A1 (en) 2023-08-17
AU2018234918B2 (en) 2023-11-02
NZ756504A (en) 2023-11-24
JP2020513792A (ja) 2020-05-21
EP4653536A2 (en) 2025-11-26
IL268788B2 (en) 2025-05-01
EP3596213A4 (en) 2021-02-17
JP2022092057A (ja) 2022-06-21
SG11201907653QA (en) 2019-09-27
JP7343903B2 (ja) 2023-09-13
KR20190132626A (ko) 2019-11-28
ZA202310779B (en) 2024-07-31
BR112019019158A2 (pt) 2020-05-05
CA3054942A1 (en) 2018-09-20
EP3596213A1 (en) 2020-01-22

Similar Documents

Publication Publication Date Title
MX2019011040A (es) Composiciones y metodos para potenciar la expresion genica.
CY1123823T1 (el) Βελτιωμενες συνθεσεις τ κυτταρων
CY1121217T1 (el) Μεθοδοι για συγκομιδη καλλιεργειων κυτταρου θηλαστικων
SG10201810150UA (en) Compositions and methods for enhanced gene expression in cone cells
MX2021000459A (es) Metodo para producir celulas t gamma y delta.
MX2022002624A (es) Edicion del genoma sin nucleasas.
MY192561A (en) Taurine supplemented cell culture medium and methods of use
SG10201902872YA (en) Ex vivo proliferation of epithelial cells
CY1122612T1 (el) Μεθοδος
GB2548740A (en) Methods for generation of podocytes from pluripotent stem cells and cells produced by the same
MY189819A (en) Genetically modified cells and uses thereof
BR112017018885A2 (pt) método de cultura celular para células-tronco mesenquimais
MX382223B (es) Regulacion de expresion genica mediada por nucleasa.
MX376870B (es) Metodos y composiciones para modificaciones geneticas dirigidas y metodos de uso.
MX2020009670A (es) Metodos de cultivo por perfusion y usos de los mismos.
MA39819A (fr) Méthodes et compositions d'immunomodulation
BR112017017886A2 (pt) gerando populações de células endoteliais arteriais
TW201612308A (en) Collector architecture layout design
MX2016013849A (es) Un factor de secrecion de proteinas con alta eficacia secretora y un vector de expresion que lo comprende.
BR112018070293A2 (pt) diferenciação de células-tronco pluripotentes em células do endoderma intestinal do intestino médio
MX2018012872A (es) Composiciones y metodos para mejorar la expresion genetica de pklr.
EA201791233A1 (ru) Материал стволовых клеток и способ его получения
MX2016012102A (es) Metodos relacionados con celulas pluripotentes.
BR112017024855A2 (pt) métodos de produção de aldc
MX2017007492A (es) Prevención y tratamiento de condiciones inflamatorias.